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INTRODUCTION
Cancer is the second leading cause of death in the United 
States. A total of 1,685,210 new cancer cases were expected to 
be diagnosed in 2016, with 595,650 expected deaths [1]. Of 
these, 249,260 newly diagnosed breast cancer cases were esti-
mated, with 40,890 expected deaths. Breast cancer makes up 
14.79% of the total expected cancer diagnoses and 6.86% of 
the total expected cancer related deaths for both sexes in the 
United States. In women, breast cancer is expected to account 
for 29% of new cancer diagnoses. While breast cancer patients 
have increased survival rates in comparison with other cancer 
types, the high incidence places breast cancer as one of the 
most common causes of cancer-related deaths [1]. Since 1990, 
the rate of mortality from breast cancer has been declining 
due to improved treatments and early detection methods [2]. 
These have been shown to be important predictors of survival, 
as early detection has been associated with reduced breast 
cancer morbidity and mortality rates [3]. 
A key component in identifying the appropriate treatment 
course is an evaluation of the cancer at the time of diagnosis 
[4]. Breast cancer staging is a method of determining severity 
of the disease and may include a physical examination of the 
skin, mammary glands, and lymph nodes, with the axillary, 
supraclavicular, and cervical nodes as the primary nodes of 
evaluation [5]. Different methods exist for classifying clinical 
and pathological findings into stages, though the most com-
monly used guidelines in the world are from the American 
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Purpose: Previous oncological studies showed that lymph node 
ratio (LNR) (ratio of number of lymph nodes that tested positive 
for metastasis to the total number of lymph nodes examined) is a 
negative indicator of cancer survival. The American Joint Committee 
on Cancer (AJCC) staging system incorporates tumor size, 
lymph node involvement, and metastasis in a comprehensive 
model of cancer progression, but LNR alone has been shown to 
outperform the AJCC system in prognostic and survival predic-
tions for various types of cancer. The effectiveness of LNR has 
not been evaluated in breast cancer staging. Evaluating LNR for 
predicting cancer staging in breast cancer has the potential to 
improve treatment recommendations. Methods: The Surveillance, 
Epidemiology, and End Results dataset was used to identify 
10,655 breast cancer patients who underwent nodal evaluation 
from 2010 to 2013, and their LNRs were calculated. Descriptive 
statistics of lymph node evaluation in the patients are provided. 
Logistic regression with LNR as the continuous independent 
variable was conducted to determine whether LNR could predict 
cancer progression, coded as regional or distant. Analysis was 
conducted using SPSS version 24. Results: Patient’s mean age 
was 59.43±18.62. Logistic regression analysis revealed that for 
every 1.3% increase in LNR, the odds of falling into the distant 
stage of the TNM staging system increased by 13.7% (odds ratio, 
14.73; 95% confidence interval, 12.00–18.08). Conclusion: LNR, 
while correlated with breast cancer staging, serves as a better 
predictor of survival. Precision staging can influence treatment 
modality, and improved treatments can significantly improve 
quality of life. Additional research and diagnostic examinations 
using LNR as a potential tool for accurate staging in breast can-
cer patients are warranted.
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Joint Committee on Cancer (AJCC) [6]. The AJCC staging 
system is standardized, with specifically defined criteria for 
each known stage of breast cancer. The system has traditional-
ly included the size of the tumor (T), the extent of spreading 
to the regional lymph nodes (N), along with the presence of 
metastasis to relatively distal areas (M) with numbers and 
lowercase letters for subtyping as needed (e.g., T1a, T1N2M0). 
The tumor can be measured based on its clinical features, ap-
pearance on imagery, size, and growth. Extent of spreading to 
regional lymph nodes is typically staged by pathology of tissue 
samples obtained by biopsy, which is known as pathologic 
staging (pN). pN staging is the most accurate way to assess 
nodal involvement because of the distinctive histological pro-
files of tumor cells. Collectively, these categories coupled with 
the metastasis staging are known as the TNM staging system. 
Even though the extent of metastasis is critical to assess a 
patient’s prognosis, the classifications have proven to be diffi-
cult to define further than “evidence of tumor cells in areas 
beyond the tumor site and regional lymph nodes.” This may 
be due to the lack of clinical presentation of the pathological 
M0 stage which can only be proven at autopsy. The 7th edi-
tion of the AJCC’s staging system raised this issue, yet the 
staging for this category remained the same in the AJCC’s 8th 
edition. Also mentioned were isolated tumor cells which are 
single or small clusters of submillimeter tumor cells which 
could be indicative of distant metastasis. These have not been 
assessed for their role in cancer prognosis. With these contin-
ually unaddressed gaps in classification and additions to treat-
ment protocols such as neoadjuvant therapy and multigene 
panel screening, it is important to consider the use of comple-
mentary staging systems. The AJCC released the 8th edition 
of its cancer staging manual in 2017 with major changes rec-
ommended for breast cancer staging [7,8]. The new consensus 
staging system maintained the TNM staging but added in-
creased details of tumor dimension parameters, consideration 
of neoadjuvant therapy, and adjustments for multigene panels 
for cancers with known genetic etiologies that allow more 
flexibility and precision for breast cancer staging. Breast can-
cer subtypes were categorized by involvement of several hor-
mone receptors which are commonly implicated in breast 
cancer: human epidermal growth factor receptor 2 (HER2), 
estrogen receptor (ER), and progesterone receptor (PR) [9]. 
Gándara-Cortes et al. [10] elucidated targeted and sensitive 
treatments for cancers characterized by the involvement of 
these receptors. Prognosis generally tended to be worse for 
those diagnosed with triple-negative (HER2–/ER–/PR–) and 
HER2-positive breast cancers, though cases within a specific 
subtype will vary somewhat in presentation [11,12]. This 
combined TNM and subtype staging system is better at pre-
dicting survival for breast cancer than either staging system 
alone [13], indicating that even the most updated version of 
the AJCC manual needed the extra nuances of a supplemen-
tary staging system. 
The addition of new staging criteria reflects an awareness of 
concerns with the TNM approach, not just in breast cancer 
but in multiple areas of oncology. Recently, the evaluation of 
lymph node ratio (LNR) in gastric cancer staging was shown 
to outperform the 7th edition guidelines of the AJCC’s TNM 
staging system in sensitivity measures and overall survival 
[14]. LNR also proved useful in the prognosis of postsurgical 
pancreatic cancer patients as one of the most powerful predic-
tors of survival time [15]. The 7th edition of the AJCC’s stag-
ing system requires the examination of 15 lymph nodes for 
accurate staging and classifies stage by location of the involved 
nodes. Yet, the examination of 15 lymph nodes is often not 
performed as some nodes are unavailable for resection, result-
ing in under-staging. Increased identification of involved 
nodes and surgical resections of these nodes resulted in in-
creased staging accuracy and colon cancer survival prediction 
[16]. Inadequate analysis of lymph node involvement is a re-
sult of certain types of operations or a tumor with few local 
lymph nodes for assessment. LNR has been used to augment 
staging determination and successfully predict prognosis [17]. 
Even in cases where sufficient nodal resection was performed, 
LNR has been shown to be superior to the AJCC’s staging sys-
tem via the assessment of the number of positive lymph nodes 
for predicting prognosis in colon cancer [18]. Survival rates 
predicted with LNR, metastatic lymph nodes, and log odds of 
positive lymph nodes as the staging method were superior to 
the AJCC’s 7th edition TNM staging system in rare perihilar 
cholangiocarcinoma as well [19].  
There is evidence of the prognostic value in using LNR to 
predict breast cancer survival from multiple small studies 
(sample sizes of less than 1,800) [20] and limited studies of 
larger size [21,22]. There are a number of factors that can in-
terfere with the value of LNR as a useful tool for prognosis in 
breast cancer, including very large tumor sizes or advanced 
disease, very-early stage disease, residual disease, or the use of 
neoadjuvant therapy which can interfere with nodal evalua-
tion [23], though other research shows LNR is effective for 
prognostic prediction of high-risk breast cancers, even when 
neoadjuvant therapy is used [24]. In one study combining 
multiple cancer trials for an overall analysis of over 7,000 
breast cancer patients, LNR was useful for prognosis in a sub-
set of patients with 1–3 affected lymph nodes [25]. The effec-
tiveness of LNR as a prognostic indicator has resulted in sug-
gestions for inclusion of LNR in breast cancer staging [21].
Newer research as well as AJCC’s 8th edition staging system 
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has focused on breast can cer subtypes as an adjunct to surviv-
al prediction and will be an important part of prospective 
studies. However, the recent development of assays and imag-
ing approaches to identify the genetic subtypes are still under 
development and range in both cost and availability [10,26, 
27], making large scale analysis inaccessible at present. The 
purpose of this study was to access the large number of sam-
ples available in a national cancer data registry to evaluate the 
effectiveness of LNR in predicting breast cancer survival com-
pared to TNM staging.
METHODS
The study employed a retrospective analysis of The Surveil-
lance, Epidemiology, and End Results (SEER) dataset. The 
SEER dataset collects information from 12 population-based 
cancer registries which comprise 14% of the United States 
population. Patient demographic information, cancer diagno-
sis, and clinical indicators such as primary tumor size, grade, 
and extension were obtained on 10,651 breast cancer patients 
who underwent nodal evaluation between 2010 and 2013. 
These characteristics were examined and reported with de-
scriptive statistics (Table 1).
The definitions in the SEER summary staging manual were 
used to distinguish each summary stage of breast cancer. The 
localized stage cases were excluded from analysis because the 
localized stage is the only stage aside from the in situ stage that 
does not include any measurable or significant degree of 
lymph node involvement. The intrinsic nature of these stages 
precludes their ability to participate in the evaluation of a 
lymph node-based staging system. SEER defines regional 
lymph nodes as the most proximal lymph nodes which serve 
as immediate drainage sites for the site of the tumor and are 
therefore good indicators for the metastatic behavior of the 
cancer. For tumors of the breast, these include the axillary 
lymphatic plexus, paramammary lymph nodes, and interpec-
toral axillary lymph nodes. 
Metastasis classifications are binary: M0 (no distant metas-
tasis) or M1 (distant metastasis). LNR was calculated as the 
number of lymph nodes tested positive for metastasis after re-
section divided by the total number of lymph nodes that were 
examined. Local, regional, and distant SEER categorizations 
are determined by the TNM staging system and incorporate 
factors of tumor size, multiplicity, depth of invasion, extension 
to regional or remote areas, and histologic grade, in addition 
to lymph node involvement. Independent sample t-tests were 
run to test the hypothesis that staging and LNR are each asso-
ciated with survival months. Correlational analysis was con-
ducted to examine the relationship between LNR and TNM 
staging. Logistic regression was performed using SPSS version 
24 (IBM Corp., Armonk, USA) to identify whether LNR and 
TNM staging could predict survival months, and whether 
LNR could predict cancer staging as either local, regional, or 
distant.  
RESULTS
There were 10,523 women (98.8%) and 132 men (1.2%) in-
cluded in the study. Patient’s mean age was 59.43 ± 18.62 
(Table 1). There were 267 individuals under age 35 years; aged 
35–54 years, 3,848; aged 55–75 years, 5,117; and over age 75 
years, 1,423. Only two patients were in the localized group, 
thus these cases were excluded due to the small sample size. A 
total of 9,736 individuals (91.4%) were identified to be in the 
regional cancer stage group, and 913 (8.6%) in the distant 
cancer stage group (Figure 1). There were 7,423 cases (59.7%) 
that had 15 or fewer nodes examined (Table 2). A chi-square 
test was performed but no relationship was found between 
age and LNR (χ2(3, N= 10,647)= 5.03; p= 0.170).  
LNR and TNM staging for the classification of cases into ei-
ther regional or distant cancer stages had a Spearman’s rho of 




   Female 10,523 (98.8)
   Male 132 (1.2)
Race
   White 8,426 (79.1)
   Black 1,201 (11.3)
   Asian or Pacific Islander 883 (8.3)
   Other 60 (0.6)
   Unknown 85 (0.8)
Location
   San Francisco 9 (0.1)
   Connecticut 2,728 (25.6)
   Detroit 3,252 (30.5)
   Hawaii 1,047 (9.8)
   Iowa 2,233 (21.0)
   New Mexico 1,382 (13.0)
   Missing 4 (0.1)
Breast subtype
   HER2+/HR+ 1,172 (11.0)
   HER2+/HR– 519 (4.9)
   HER2–/HR+ 7,285 (68.4)
   Triple-negative 1,189 (11.1)
   Missing 490 (4.6)
SEER=Surveillance, Epidemiology, and End Results; HER2=human epider-
mal growth factor receptor 2; HR=hormone receptor.
*Mean±SD.
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0.237, which was a small but significant correlation (p <  
0.001). LNR was negatively correlated with survival months 
(r= –0.113, p< 0.001) such that a lower ratio of positive nodes 
resulted in longer survival months. Linear regression analysis 
found that LNR was a stronger predictor of survival months 
(β = –0.113, p < 0.001, r2 = 0.013) than TNM staging (β =  
–0.050, p< 0.001, r2 = 0.002) for both regional and distant can-
cer stages (Table 3). Other multivariate models were tested, 
including the addition of age at diagnosis and breast can cer 
subtypes, but these variables did not alter the significance of 
LNR in predicting survival months (results available upon re-
quest). LNR, while more predictive of survival months, was 
related to TNM staging as logistic regression analysis revealed 
that for every 1% increase in LNR, the odds of falling into the 
distant cancer stage of the TNM staging system increased by 
13.7% (odds ratio, 14.73; 95% confidence interval, 12.00–
18.08).
DISCUSSION
In this study, we sought to evaluate the prognostic value of 
LNR within the breast cancer node positive cohort of the 
SEER dataset in comparison to the survival prediction value 
of the TNM staging system in SEER. It is well-established that 
LNR can be a strong prognosis factor for several cancer types 
[18]. More specifically, the prognostic use of LNR in breast 
cancer has been shown to be a significant predictor of patient 
overall survival, spanning all stages of breast cancer and vari-
ous treatment types [20,22,28]. The present analysis used a 
larger cohort of the SEER cancer registry than previous stud-
ies to compare the predictive value of LNR to TNM staging in 
breast cancer survival for a diverse patient population, which 
is necessary for the findings to reflect the impact on the popu-
lation at large. 
We found that while LNR and TNM cancer staging have a 
small but significant correlation, LNR was a better predictor 
of survival than TNM. Our results, while consistent with pre-
vious studies that showed LNR may be warranted as a superi-
or method of breast cancer prognosis, also found that LNR 
exponentially increases the odds of falling into the distant 
stage of the TNM cancer staging system. This association be-
tween LNR and distant stage TNM potentially explains the 
higher prediction value of LNR over TNM staging. 
The present study on a broad population of over 10,000 
breast cancer patients evaluated whether LNR would be a use-
ful prognostic indicator for today’s oncology providers. LNR 
was able to provide a greater prediction of overall survival 
than TNM staging, though the r2 value suggested that just 
over 1% of the variation in survival months could be ex-
plained by LNR. While statistically significant, this level of 
prediction may not be clinically meaningful or relevant for 
treatment considerations for cases without node involvement, 
or node-negative cases. This finding was consistent with other 
LNR analyses that suggested only a small, defined subpopula-
tion of breast cancer patients would benefit from the use of 
LNR [25]. The analysis could have benefited from the consis-
tent implementation of active post-study follow-up. Several 
SEER regions input survival as a “presumed alive” date (no 
death certificate or autopsy of patient during the study period) 
Table 2. Number of nodes examined and frequency of positive nodes 
for patients in the SEER
No. of nodes  
examined
No. (%)
No. of positive 
nodes
No. (%)
1–5 3,014 (28.3) 1–5 8,755 (82.2)
6–10 1,970 (18.5) 6–10 1,086 (10.2)
11–15 2,439 (22.9) 11–15 457 (4.3)
16–20 1,747 (16.4) 16–20 202 (1.9)
21–25 873 (8.2) 21–25 85 (0.8)
>25 607 (5.7) >25 63 (0.6)
Missing 1 (0.0) Missing 3 (0.0)
SEER=Surveillance, Epidemiology, and End Results.
Table 3. Regression analyses: LNR and staging on survival months
β Standard 
error
t p-value  r2
Intercept of LNR 24.133 0.209




Regional/distant stage –2.456 0.477 –5.154 <0.001 0.002
LNR= lymph node ratio.
Figure 1. Distribution of the Surveillance, Epidemiology, and End Re-
























Breast Cancer Survival Using Lymph Node Ratio 319
https://doi.org/10.4048/jbc.2018.21.e35 http://ejbc.kr
as the study end date, which was December 31, 2013. Other 
regions proceeded with active follow-up and gave “date of last 
contact” (with the research staff) as date of survival.
To incorporate LNR meaningfully into clinical practice, the 
relationship between ratios and changes in ability to predict 
overall survival must be defined. The AJCC reviews their 
guidelines among multitudes of researchers and physicians to 
update the system’s parameters on a regular basis. Reviews 
have found the range of LNR between 0.20 and 0.65 to be the 
most common cutoff points for increases and decreases in 
overall survival [29]. Future studies should investigate and 
suggest guidelines for evaluating these ratios. 
Broad level analysis is limited by the inclusion of almost all 
breast cancer types and levels of disease progression, which 
are factors that can inhibit the usefulness of LNR in survival 
prediction [23]. It should be understood that the patient pop-
ulation chosen for analysis excluded those with in situ and lo-
calized stage diagnoses due to the nature of the lymph node 
biopsy procedure. Including subtype in the analysis did not 
alter the significance of LNR as a predictor of survival months. 
Additionally, the presence and extent of study variables in-
cluding survival months depended on the SEER region col-
lecting the data, as some regions provided active patient fol-
low-up while some regions used recorded data to determine 
survival status. The analysis was also constrained because the 
SEER variable identifying sentinel lymph node biopsy versus 
axillary lymph node dissection was found to be prone to un-
derestimation due to data collection procedures, making the 
data unavailable as a consideration in the current analysis [30]. 
However, the inaccurate collection procedures were rectified 
in 2012 and should be included in future analysis of the utility 
of lymph node dissection in cancer staging. 
The focus in all the updates to the AJCC 8th edition guide-
lines is on cancers with the detectable biomarkers of ER, PR, 
and HER2, and cases that are post-neoadjuvant therapy. Neo-
adjuvant therapies are systemic treatments that are now in-
cluded in therapeutic recommendations to downstage cases of 
advanced breast cancer prior to surgical intervention. Accu-
rate staging of disease after the administration of neoadjuvant 
therapy is even more imperative due to its predictive role in 
determining risk of recurrence. Persistence of tumor growth 
in lymph nodes despite prophylactic treatment warrants a 
more strategic approach to treatment. For this reason, LNR is 
worth considering as a supplementary staging technique for 
the goal of attaining complete pathological response, which 
means there is no evidence of invasive cancer left in the pa-
tient. This is only attained when the post-neoadjuvant AJCC 
stage of the disease is T0/is and N0, meaning there is no pri-
mary tumor as well as no evidence of metastatic spread to the 
axillary lymph nodes. Of note, the use of neoadjuvant thera-
pies will likely decrease the number of cases staged as distant 
metastasis, a consideration for the refinement of future LNR 
research to be specific and attentive to regional node metasta-
sis. The success of LNR for the prediction of survival in the 
nebulous and possibly less predictable intermediate stages 
warrants research into a supplementary role as the impact of 
biologically-based intervention on prognosis changes the 
landscape of breast oncology. Further investigation should 
evaluate known breast can cer subtypes that exhibit aggressive 
metastasis as well as survival rates for the concurrent usage of 
the AJCC and LNR staging systems. 
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